LA

LakeShore Biopharma

2 known investors

lakeshorebio.com ↗

Lakeshore Biopharma (Nasdaq: LSB, formerly Yisheng Biopharma) is a biopharmaceutical company focused on developing, producing, and selling vaccines and immunological products for infectious diseases. Its main marketed product is a lyophilized human rabies vaccine (Vero cell), and it uses a proprietary PIKA immunomodulating technology.

Investors · 2

AD

Adjuvant CapitalNew York · $10M – $25M

F-

F-Prime Capital PartnersCambridge · $3M – $10M